{"id":946,"date":"2019-12-16T09:16:40","date_gmt":"2019-12-15T20:16:40","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=946"},"modified":"2019-12-16T09:16:40","modified_gmt":"2019-12-15T20:16:40","slug":"ibrutinib-and-venetoclax-combo-impressive-in-front-line-cll","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=946","title":{"rendered":"Ibrutinib and Venetoclax Combo \u2018Impressive\u2019 in Front-Line CLL"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row row_height_percent=&#8221;0&#8243; override_padding=&#8221;yes&#8221; h_padding=&#8221;2&#8243; top_padding=&#8221;3&#8243; bottom_padding=&#8221;3&#8243; overlay_alpha=&#8221;50&#8243; gutter_size=&#8221;3&#8243; column_width_percent=&#8221;100&#8243; shift_y=&#8221;0&#8243; z_index=&#8221;0&#8243;][vc_column width=&#8221;1\/1&#8243;][vc_custom_heading heading_semantic=&#8221;h1&#8243; text_size=&#8221;h1&#8243;]Ibrutinib and Venetoclax Combo \u2018Impressive\u2019 in Front-Line CLL[\/vc_custom_heading][vc_column_text]The combination of two targeted therapies \u2014 ibrutinib (Imbruvika, Pharmacyclics\/Janssen) and venetoclax (Venclexta, AbbVie) \u2013 has shown impressive results in the front-line treatment of chronic lymphocytic leukemia (CLL).<\/p>\n<p>To read the full story visit <a href=\"https:\/\/www.medscape.com\/viewarticle\/913653\" target=\"_blank\" rel=\"noopener noreferrer\">Medscape<\/a>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The combination of two targeted therapies \u2014 ibrutinib (Imbruvika, Pharmacyclics\/Janssen) and venetoclax (Venclexta, AbbVie) \u2013 has shown impressive results in the front-line treatment of chronic lymphocytic leukemia (CLL).<\/p>\n","protected":false},"author":1,"featured_media":941,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2019\/12\/unnamed.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=946"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/946\/revisions"}],"predecessor-version":[{"id":947,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/946\/revisions\/947"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/941"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}